THE EFFECTIVENESS OF PRASTERONE VS PLACEBO THERAPY AS THE VULVOVAGINAL ATROPHY TREATMENT IN MENOPAUSAL WOMEN: META-ANALYSIS STUDY
Article Sidebar
Main Article Content
Abstract
Background : Vulvovaginal atrophy is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue. Objective : This paper aims to evaluate the effectiveness of administering Prasterone as Vulvovaginal Atrophy therapy in menopausal women. Methods : A systematic data search was performed on a medical database (PUBMED, Google scholar, Cochrane). Inclusion criteria: (1) randomized study of Prasterone as Vulvovaginal Atrophy therapy in postmenopausal women, (2) all-inclusive papers can be accessed completely, and (3) the data obtained can be accurately analysed. Results: Three RCTs with a total of 696 patients were analysed. The average number of Superficial Cells (mean difference [MD] 7.63, and 95% [CI] 7.57 to 7.70 (P <0.00001). The average number of Parabasal Cells (mean difference [MD] -29.84, and 95% [CI] -30.25 to -29.44 (P <0.00001). The average number of vaginal pH (mean difference [MD] -0.69, and 95% [CI] -0.70 to -0.68 (P <0.00001). The average number of Dyspareunia (mean difference [MD] -0.38, and 95% [CI] -0.39 to -0.37 (P <0.00001). All diamonds do not intersect the vertical line, and have p <0.05, it proves that there are significant differences between the two groups. All non-hysterectomized women have an atrophic or inactive endometrium. Side effects that are often complained of is headache and application site discharge. Conclusion This meta-analysis concludes that Prasterone therapy has a significant therapeutic effect for Vulvovaginal Atrophy in menopausal women
Downloads
Article Details
Copyright (c) 2020 Zettira Maulida Prasha, Hari Paraton
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452–61.
Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016;215(6):704–11
Labrie F, Belanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702–12.
Archer DF, Labrie F, Montesino M, et al. Comparison of intra- vaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1–8.
European Medicines Agency. Intrarosa: summary of product characteristics. 2019. http://www.ema.europa.eu/. Accessed 20 June 2019.
AMAG Pharmaceuticals. Intrarosa (prasterone insert): US prescribing information. 2018. http://www.fda.gov. Accessed 31 May 2019.
Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandros- terone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282-288
Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (prasterone). Menopause 2015;22:950-963.
Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA)on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.